|
Rubicon Research ((Rubicon Research Pvt. Ltd ).) is a contract research and a Drug delivery company Located in Mumbai, India. In formulation development, Rubicon has a presence in all therapeutic areas excluding cytotoxic drugs, beta-lactum antibiotics and steroids. Kotak Private Equity has invested in Rubicon Research. ==History== Rubicon Research was founded by Ms. Pratibha Pilgaonkar (CEO), Mr. Sudhir Pilgaonkar (CFO) and Ms. Maharukh Rustomjee(COO) in the year 1999. Rubicon Research started its operations in contract research primarily in the R & D center located in Bhandup, Mumbai with three scientists in a laboratory in 2000. In 2003, the Directorate of Science and Technology, Government of India approved the facilities as a commercial Research and Development (R&D) company. In 2006-07 Rubicon licensed its Orodispersible excipient, RubiODT to Mallinckrodt Baker, Inc.〔Pharmaceutical online : Mallinckrodt Baker And Rubicon Research Sign Agreement For Performance Excipient Development〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Rubicon Research」の詳細全文を読む スポンサード リンク
|